Chapter 50: Anemias – Iron & Erythropoietin Therapy

The comprehensive Chapter 50 on Anemias from Pharmacotherapeutics for Advanced Practice: A Practical Approach (5th Edition) details the pathophysiology, diagnostic evaluation, and pharmacologic management of conditions defined by a decrease in circulating red blood cells (RBCs) or hemoglobin, which subsequently reduces the blood's capacity to transport oxygen. Anemias are classified based on their underlying cause, such as increased destruction (e.g., acute posthemorrhagic anemia or inherited hemolytic disorders like Sickle Cell Disease (SCD)) or diminished RBC production. Classification is also done by cell size using the mean corpuscular volume (MCV), distinguishing between microcytic (e.g., Iron Deficiency Anemia [IDA], Thalassemia), normocytic (e.g., Anemia of Chronic Disease), and macrocytic anemias (e.g., Folate or Vitamin B12 deficiency). Evaluation relies on a thorough history, physical examination, and laboratory testing including a Complete Blood Count (CBC) and specialized studies like iron parameters or reticulocyte counts. Treatment is dictated by the specific etiology; IDA, the most common nutritional deficiency worldwide, is managed with oral iron replacement and agents that enhance absorption, such as Vitamin C. Macrocytic anemias, particularly Vitamin B12 deficiency, necessitate cyanocobalamin replacement, noting that B12 deficiency can lead to irreversible neurological damage if untreated. For Anemia of Chronic Renal Failure (CKD), which is primarily caused by reduced endogenous erythropoietin (EPO) production, therapy involves ensuring adequate iron stores and administering Erythropoiesis-Stimulating Agents (ESAs) like epoetin or darbepoetin to target a hemoglobin concentration of 10 to 12 g/dL. Inherited conditions such as SCD, characterized by vaso-occlusive crises, are managed with prophylactic medications like hydroxyurea or voxelotor to reduce crises and, acutely, with aggressive pain relief. Other conditions, including hereditary Thalassemia, often require lifelong transfusions and iron chelation therapy to combat resulting hemosiderosis. Regardless of the type, treatment should only be initiated once a specific diagnosis is made, with the goal of improving quality of life and preventing complications.